Dr. Barone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9000 Lockhart Gardens
St. Thomas, VI 00802Phone+1 340-774-2015
Summary
- Leverage C-Suite-level clinical development and regulatory experience in both public and private company settings to provide strategic and execution consulting services across a range of indications in ophthalmology, dermatology, rare diseases, and cell and gene therapy.
Education & Training
University of California (San Diego) Medical CenterFellowship, Surgical Retina and Vitreous, 2007 - 2009
Icahn School of Medicine at Mount Sinai/New York Eye and Ear Infirmary at Mount SinaiResidency, Ophthalmology, 2004 - 2007
National Capital ConsortiumInternship, Transitional Year, 1999 - 2000
Pennsylvania State University College of MedicineClass of 1999
Certifications & Licensure
MD State Medical License 2000 - 2026
VA State Medical License 2010 - 2026
CA State Medical License 2007 - 2025
VI State Medical License 2020 - 2024
DC State Medical License 2010 - 2013
NY State Medical License 2004 - 2010- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2012-2013
Publications & Presentations
PubMed
- 9 citationsEvaluation of optic neuritis following human papillomavirus vaccinationGayathri Sridhar, Fang Tian, Richard A. Forshee, Martin Kulldorff, Nandini Selvam
Human Vaccines & Immunotherapeutics. 2017-05-02 - 109 citationsPhase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular DegenerationIan J. Constable, Cora M. Pierce, Chooi May Lai, Aaron L. Magno, Mariapia A. Degli-Esposti
Ebiomedicine. 2016-12-01 - 9 citationsA Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy.Arshad M Khanani, Raj K Maturi, Nika Bagheri, Benjamin Bakall, David S Boyer
Ophthalmology Science. 2022-06-01
Press Mentions
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 VirtualSeptember 9th, 2021- Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the SummitAugust 30th, 2021
- Gemini Therapeutics Announces Initial Data from Its Ongoing Phase 2a Study of GEM103 in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationJune 22nd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
